Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 1Phase 1 1

Status

Active not recruiting 3Terminated 1Recruiting 1Completed 1

Sponsor Class

OTHER 5INDUSTRY 1

Study Type

Interventional 6

Sponsor

Cancer Type

Genitourinary 6

Conditions

Prostatic Neoplasms 6Ovarian Neoplasms 3Breast Neoplasms 3Prostatic Neoplasms, Castration-Resistant 2Fallopian Tube Neoplasms 2Triple Negative Breast Neoplasms 1Pathologic Complete Response 1Neoplasms 1Neoplasm Metastasis 1Metastatic Castration-sensitive Prostate Cancer 1Hemangiosarcoma 1Head and Neck Neoplasms 1Carcinoma, Ovarian Epithelial 1Biliary Tract Neoplasms 1

Interventions

Magnetic Resonance Spectroscopy 28enzalutamide 23Specimen Handling 20apalutamide 17Androgen Antagonists 14Radiosurgery 13Radiotherapy 12Prednisone 12Docetaxel 12Abiraterone Acetate 12abiraterone 10Biopsy 10Radiation 8niraparib 6luprolide acetate gel depot 6darolutamide 6Pluvicto 6Leuprolide 62-(3-(1-carboxy-5-((6-fluoropyridine-3-carbonyl)amino)pentyl)ureido)pentanedioic acid 6relugolix 5gallium 68 PSMA-11 5cabazitaxel 5acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 5Nivolumab 5Gonadotropin-Releasing Hormone 5bicalutamide 4Triptorelin Pamoate 4Surveys and Questionnaires 4Radiotherapy, Intensity-Modulated 4Glutamate Carboxypeptidase II 4

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
Prostatic Neoplasms × niraparib × 30 days × Clear all
NCT04037254 2026-05-20

Testing the Addition of a New Anti-Cancer Drug, Niraparib, to the Usual Treatment (Hormone and Radiation Therapy) for Prostate Cancer With a High Chance of Recurring

NRG Oncology

Phase 1/2 Completed
22 enrolled 13 charts
Genitourinary

Prostatic Neoplasms

NCT04947254 2026-05-15

Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer

M.D. Anderson Cancer Center

Phase 2 Recruiting
200 enrolled
Genitourinary

Prostatic Neoplasms

NCT04030559 2026-05-14

Niraparib Before Surgery in Treating Patients With High Risk Localized Prostate Cancer and DNA Damage Response Defects

University of California, Davis

Phase 2 Terminated
11 enrolled 7 charts
Genitourinary

Prostatic Neoplasms

NCT05689021 2026-05-11

CJNJ-67652000 and Prednisone for Treatment of Metastatic Castration-Resistant Prostate Cancer and SPOP Gene Mutations

Mayo Clinic

Phase 2 Active not recruiting
8 enrolled
Genitourinary

Prostatic Neoplasms

NCT04577833 2026-05-08

A Study of Comparative Formulations of Niraparib and Abiraterone Acetate (AA) in Men With Prostate Cancer

Janssen Research & Development, LLC

Phase 1 Active not recruiting
136 enrolled
Genitourinary

Prostatic Neoplasms

NCT06212583 2026-05-06

KNIGHTS

University of Maryland, Baltimore

Phase 2 Active not recruiting
88 enrolled
Genitourinary

Prostatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡